弥財的个人主页 - 老虎社区

弥財

暂无个人介绍

IP属地：辽宁

144关注

7粉丝

2主题

0勋章

2021-02-04

多参与老虎社区活动，有助中签

2022-09-15

十年后再看吧[流泪]

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3573800024752002","uuid":"3573800024752002","gmtCreate":1610706001513,"gmtModify":1616399837463,"name":"弥財","pinyin":"m財mi財","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/dfd000198e85105a40765fbbdc35254f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":7,"headSize":144,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":2,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":7,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"辽宁","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":663232208,"gmtCreate":1663209138504,"gmtModify":1663209699153,"author":{"id":"3573800024752002","authorId":"3573800024752002","name":"弥財","avatar":"https://static.tigerbbs.com/dfd000198e85105a40765fbbdc35254f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573800024752002","authorIdStr":"3573800024752002"},"themes":[],"htmlText":"十年后再看吧[流泪]&nbsp;","listText":"十年后再看吧[流泪]&nbsp;","text":"十年后再看吧[流泪]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/663232208","repostId":"2262936056","repostType":2,"repost":{"id":"2262936056","kind":"news","pubTimestamp":1661422271,"share":"https://www.laohu8.com/m/news/2262936056?lang=&edition=full","pubTime":"2022-08-25 18:11","market":"hk","language":"zh","title":"一图看懂兆科眼科-B(06622.HK)2022年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2262936056","media":"格隆汇","summary":"2022年8月24日晚间，兆科眼科-B(06622.HK)发布截至2022年6月30日止6个月的中期业绩，公司的药物组合包含创新药及仿制药，针对影响眼前节及眼后节的六大眼科疾病，在眼科行业中规模最大，效用最全面。公司的管线中有多种可能疗效显着的候选创新药，相信可望成为同类最佳及同类首创疗法，未来将为公司的收益作出重大贡献。公司通过进取的增长策略，包括与国内外药厂合作，锐意成为中国以至全球眼科行业领先企业。下面让我们通过一图看懂兆科眼科-B(06622.HK)2022年中期业绩。","content":"<html><body><article><p>2022年8月24日晚间，<a href=\"https://laohu8.com/S/06622\">兆科眼科-B</a>(06622.HK)发布截至2022年6月30日止6个月的中期业绩，公司的药物组合包含创新药及仿制药，针对影响眼前节及眼后节的六大眼科疾病，在眼科行业中规模最大，效用最全面。公司的管线中有多种可能疗效显着的候选创新药，相信可望成为同类最佳及同类首创疗法，未来将为公司的收益作出重大贡献。公司通过进取的增长策略，包括与国内外药厂合作，锐意成为中国以至全球眼科行业领先企业。</p><p>下面让我们通过一图看懂兆科眼科-B(06622.HK)2022年中期业绩。</p><img src=\"https://img3.gelonghui.com/2b445-c4fbfea2-c767-417f-aeb8-da2371418506.jpg\"/></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>一图看懂兆科眼科-B(06622.HK)2022年中期业绩</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n一图看懂兆科眼科-B(06622.HK)2022年中期业绩\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-25 18:11 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20220825181130821c3d83&s=b><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2022年8月24日晚间，兆科眼科-B(06622.HK)发布截至2022年6月30日止6个月的中期业绩，公司的药物组合包含创新药及仿制药，针对影响眼前节及眼后节的六大眼科疾病，在眼科行业中规模最大，效用最全面。公司的管线中有多种可能疗效显着的候选创新药，相信可望成为同类最佳及同类首创疗法，未来将为公司的收益作出重大贡献。公司通过进取的增长策略，包括与国内外药厂合作，锐意成为中国以至全球眼科行业...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20220825181130821c3d83&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1587":"次新股","06622":"兆科眼科-B","BK1191":"制药","BK1574":"生物医药B类股","BK1583":"高瓴概念"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20220825181130821c3d83&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2262936056","content_text":"2022年8月24日晚间，兆科眼科-B(06622.HK)发布截至2022年6月30日止6个月的中期业绩，公司的药物组合包含创新药及仿制药，针对影响眼前节及眼后节的六大眼科疾病，在眼科行业中规模最大，效用最全面。公司的管线中有多种可能疗效显着的候选创新药，相信可望成为同类最佳及同类首创疗法，未来将为公司的收益作出重大贡献。公司通过进取的增长策略，包括与国内外药厂合作，锐意成为中国以至全球眼科行业领先企业。下面让我们通过一图看懂兆科眼科-B(06622.HK)2022年中期业绩。","news_type":1},"isVote":1,"tweetType":1,"viewCount":2407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":317180663,"gmtCreate":1612427876352,"gmtModify":1703761686399,"author":{"id":"3573800024752002","authorId":"3573800024752002","name":"弥財","avatar":"https://static.tigerbbs.com/dfd000198e85105a40765fbbdc35254f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573800024752002","authorIdStr":"3573800024752002"},"themes":[],"htmlText":"多参与老虎社区活动，有助中签","listText":"多参与老虎社区活动，有助中签","text":"多参与老虎社区活动，有助中签","images":[{"img":"https://static.tigerbbs.com/34947c163e899c689fa482d7672e3140","width":"750","height":"1334"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/317180663","isVote":1,"tweetType":1,"viewCount":3290,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3573800024752002","authorId":"3573800024752002","name":"弥財","avatar":"https://static.tigerbbs.com/dfd000198e85105a40765fbbdc35254f","crmLevel":2,"crmLevelSwitch":0,"idStr":"3573800024752002","authorIdStr":"3573800024752002"},"content":"中个快手就飘了!痛定思痛，已制定合理计划，严格执行。","text":"中个快手就飘了!痛定思痛，已制定合理计划，严格执行。","html":"中个快手就飘了!痛定思痛，已制定合理计划，严格执行。"}],"imageCount":1,"langContent":"CN","totalScore":0}],"hots":[{"id":317180663,"gmtCreate":1612427876352,"gmtModify":1703761686399,"author":{"id":"3573800024752002","authorId":"3573800024752002","name":"弥財","avatar":"https://static.tigerbbs.com/dfd000198e85105a40765fbbdc35254f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573800024752002","idStr":"3573800024752002"},"themes":[],"htmlText":"多参与老虎社区活动，有助中签","listText":"多参与老虎社区活动，有助中签","text":"多参与老虎社区活动，有助中签","images":[{"img":"https://static.tigerbbs.com/34947c163e899c689fa482d7672e3140","width":"750","height":"1334"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/317180663","isVote":1,"tweetType":1,"viewCount":3290,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3573800024752002","authorId":"3573800024752002","name":"弥財","avatar":"https://static.tigerbbs.com/dfd000198e85105a40765fbbdc35254f","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3573800024752002","idStr":"3573800024752002"},"content":"中个快手就飘了!痛定思痛，已制定合理计划，严格执行。","text":"中个快手就飘了!痛定思痛，已制定合理计划，严格执行。","html":"中个快手就飘了!痛定思痛，已制定合理计划，严格执行。"}],"imageCount":1,"langContent":"CN","totalScore":0},{"id":663232208,"gmtCreate":1663209138504,"gmtModify":1663209699153,"author":{"id":"3573800024752002","authorId":"3573800024752002","name":"弥財","avatar":"https://static.tigerbbs.com/dfd000198e85105a40765fbbdc35254f","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573800024752002","idStr":"3573800024752002"},"themes":[],"htmlText":"十年后再看吧[流泪]&nbsp;","listText":"十年后再看吧[流泪]&nbsp;","text":"十年后再看吧[流泪]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/663232208","repostId":"2262936056","repostType":2,"isVote":1,"tweetType":1,"viewCount":2407,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}